Wall Street analysts predict that TESARO, Inc. (NASDAQ:TSRO) will announce $17.22 million in sales for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for TESARO’s earnings. The lowest sales estimate is $10.77 million and the highest is $24.67 million. TESARO posted sales of $36.56 million in the same quarter last year, which suggests a negative year over year growth rate of 52.9%. The business is expected to report its next earnings report on Thursday, August 3rd.

On average, analysts expect that TESARO will report full-year sales of $17.22 million for the current fiscal year, with estimates ranging from $67.34 million to $196.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $430.43 million per share, with estimates ranging from $231.30 million to $554.79 million. Zacks’ sales averages are an average based on a survey of analysts that follow TESARO.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.26) by $0.29. The firm had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.84 million. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The company’s revenue was up 909.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.22) EPS.

A number of brokerages have weighed in on TSRO. Piper Jaffray Companies began coverage on TESARO in a report on Wednesday, April 12th. They set an “overweight” rating and a $180.00 price target for the company. Cowen and Company reiterated a “market perform” rating and set a $145.00 price target on shares of TESARO in a report on Tuesday, March 28th. Cann reiterated a “buy” rating and set a $199.00 price target on shares of TESARO in a report on Monday, June 5th. FBR & Co reiterated a “hold” rating on shares of TESARO in a report on Monday, April 3rd. Finally, Citigroup Inc. reiterated a “buy” rating and set a $216.00 price target (down from $232.00) on shares of TESARO in a report on Saturday, April 22nd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. TESARO presently has an average rating of “Buy” and a consensus price target of $173.74.

TESARO (NASDAQ:TSRO) traded up 4.03% on Thursday, reaching $129.02. The company’s stock had a trading volume of 932,011 shares. The firm’s 50-day moving average price is $139.60 and its 200-day moving average price is $151.77. TESARO has a 52-week low of $83.26 and a 52-week high of $192.94. The stock’s market cap is $6.95 billion.

In other TESARO news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the transaction, the vice president now owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 40.50% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new position in TESARO during the first quarter worth about $177,000. Fox Run Management L.L.C. purchased a new position in TESARO during the second quarter valued at approximately $224,000. Private Capital Advisors Inc. purchased a new position in TESARO during the second quarter valued at approximately $232,000. Capstone Asset Management Co. purchased a new position in TESARO during the second quarter valued at approximately $238,000. Finally, Soros Fund Management LLC purchased a new position in TESARO during the first quarter valued at approximately $262,000.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/20/zacks-brokerages-expect-tesaro-inc-tsro-will-announce-quarterly-sales-of-17-22-million.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.